Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer

NCT01611558 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line

Interventions

BIOLOGICAL: Ipilimumab

Sponsor

Bristol-Myers Squibb